Skip to content
ESPT
MARKETS / BALCAO / Health care / Pharmaceuticals / BIXT
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Bioxytran, Inc. BIXT

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$-2.1M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Bioxytran, Inc. is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design. We were incorporated on June 9, 2008, as America’s Driving Ranges, Inc.. On September 21, 2018, the Company was reorganized into Bioxytran through a reverse merger to focus on the development, manufacturing and commercialization of therapeutic drugs designed to address Hypoxia and Degenerative Diseases and antiviral treatment in humans. Pharmalectin, Inc. (the “Pharmalectin”) is a subsidiary focused on the development, manufacture and commercialization of therapeutic drugs designed to address conditions related to viral diseases. Bioxytran uses Galectin inhibitors to combat the virus, SARS-CoV-2. Bioxytran is also developing treatments for hypoxic conditions, necrosis, and degenerative diseases that utilize the carrying of oxygen to affected areas for stroke, wound, and brain damage treatment.

Written from the business description in Bioxytran, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 15 April 2026. Every sentence was checked against that document before publication.

Growth

·
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2017 · Revenue 0.2 · Net income -0.3
-2M-4M
2009201220152018202120242025
Compound annual growth
−11.5%
−9.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −9.4% a year over the five years to FY2017.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2014 · Operating -464.7% · Net -488.7%
-2000%-4000%
200920172025
ROE
FY2013 · ROE -828.2%
-500%
200920172025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.
Gross margin·
Operating margin·
Net margin·
EBITDA·

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 658,552.00
Gross debtUSD 50,000.00
DepositsUSD 111,547.00
Current ratio0.16×

Not available: we don't have the cash figure for this period.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BIXT, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B◌◌◌◌◌◌◌◌0.00.00.00.00.00.00.00.0◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌
EBITDA $B◌◌◌◌◌◌◌◌−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌
Income tax $B◌◌◌◌◌◌◌0.0◌◌◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.02−0.02−0.03−0.02−0.04−0.03−0.020.00−0.01−0.03−0.21−0.30−0.47−0.02−0.06−0.01◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %————————————−828.2−886.6———
Shares out B0.110.090.140.120.110.100.090.090.090.030.010.010.190.160.11◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 71 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image